Mixture with erlotinib [13,14]. In these trials, only specific patient subsets (KRAS
Combination with erlotinib [13,14]. In these trials, only specific patient subsets (KRAS mutants, non-squamous histology and EGFR wild-type status) exhibited considerably improved PFS [14], suggesting that new TKIs will need…